THE INDIAN PHARMACIST Official Circular Pharmacy Logo THE INDIAN PHARMACISTLearn. Explore. Practise. Excel.
MEDICINE MONOGRAPH CODE: [10.8]-C113 ID: TIP-MED-000383

L-Methylfolate

Active Ingredient / Scientific Identity: L-Methylfolate • Class: Water-Soluble Haematinic & One-Carbon Methyl-Donor Vitamin (Essential for Purine/Thymidylate DNA Synthesis & Homocysteine Remethylation)

⚖️ Compare Profile
Generic / Entity NameL-Methylfolate ([10.8]-C113)
Verified Indian Brands / RefGeneric Compendial Entry (No Commercial Brand Claimed)
Pharmacological ClassWater-Soluble Haematinic & One-Carbon Methyl-Donor Vitamin (Essential for Purine/Thymidyla
Available Dosage FormsOral Uncoated Tablets: 5 mg (5000 mcg — Therapeutic/Haematinic & Methotrexate Rescue); Periconceptional Prophy
Regulatory ClassificationNon-Schedule / OTC or Schedule K Permitted Preparation (Medical Supervision Recommend
Key Warning & Review DateRenal: Safe across all stages of CKD; dialysable (5 mg OD is routinely supplemented in haemodialysis patients to replace dial
Reviewed: 2026-11-10
Safety Matrix:⚖️ Legal Status: Non-Schedule / OTC or Schedule K Permitted Preparati✔️ Standard Clinical Dispensing Precautions

1. Clinical & Scientific Overview

L-Methylfolate (TIP-MED-000383, Reference Code [10.8]-C113) is classified under Vitamins, Minerals & Nutrition — Haematinics & Iron Therapy (Ch 10) as a Water-Soluble Haematinic & One-Carbon Methyl-Donor Vitamin (Essential for Purine/Thymidylate DNA Synthesis & Homocysteine Remethylation). Within the Indian regulatory and compendial framework, it is governed under Non-Schedule / OTC or Schedule K Permitted Preparation (Medical Supervision Recommended for High-Dose/Therapeutic Regimens).

Verified Indian Market Examples / Compendial Status:
Co-indexed constituent under primary monograph [10.8] (Folic Acid (Vitamin B9 / Pteroylglutamic Acid) (and L-Methylfolate)). Representative Indian Market Examples (Edition 2.7 Ch 10 [10.8], p. 130): Folvite (Pfizer—5 mg), Folinal, Viteolin; Periconceptional 400 mcg / 500 mcg: Fol123, Folsafe; Active Metabolite (L-Methylfolate / 5-MTHF): Folate-Active, Meganeuron-OD Plus — Strengths & Dosage Forms: Oral Uncoated Tablets: 5 mg (5000 mcg — Therapeutic/Haematinic & Methotrexate Rescue); Periconceptional Prophylaxis Tablets: 400 mcg (0.4 mg) / 500 mcg (0.5 mg)
Co-indexed constituent under primary monograph [10.8] (Folic Acid (Vitamin B9 / Pteroylglutamic Acid) (and L-Methylfolate)). Representative Indian Market Examples (Edition 2.7 Ch 10 [10.8], p. 130): Folvite (Pfizer—5 mg), Folinal, Viteolin; Periconceptional 400 mcg / 500 mcg: Fol123, Folsafe; Active Metabolite (L-Methylfolate / 5-MTHF): Folate-Active, Meganeuron-OD Plus — Strengths & Dosage Forms: Oral Uncoated Tablets: 5 mg (5000 mcg — Therapeutic/Haematinic & Methotrexate Rescue); Periconceptional Prophylaxis Tablets: 400 mcg (0.4 mg) / 500 mcg (0.5 mg)
Dosage Forms & Available Strengths:
Oral Uncoated Tablets: 5 mg (5000 mcg — Therapeutic/Haematinic & Methotrexate Rescue); Periconceptional Prophylaxis Tablets: 400 mcg (0.4 mg) / 500 mcg (0.5 mg)
Routes: Oral / Parenteral / Topical per formulation

3. Mechanism of Action & Pharmacodynamics

Water-Soluble Haematinic & One-Carbon Methyl-Donor Vitamin (Essential for Purine/Thymidylate DNA Synthesis & Homocysteine Remethylation) acting on target receptor/enzyme pathways in Vitamins, Minerals & Nutrition — Haematinics & Iron Therapy (Ch 10): clinical efficacy is mediated via Water-Soluble Haematinic & One-Carbon Methyl-Donor Vitamin (Essential for Purine/Thymidylate DNA Synthesis & Homocysteine Remethylation) for 1. Prevention of Neural Tube Defects (spina bifida, anencephaly): 400 mcg/day starting at least 1–3 months before conception through Week 12 of pregnancy (5 mg/day if prior NTD history, diabetic mother, or mother taking Valproate/Carbamazepine!). 2. Folate-Deficiency Megaloblastic Anaemia and chronic haemolytic states (thalassaemia, sickle cell anaemia—5 mg OD lifelong to support rapid erythropoiesis). 3. Mandatory Co-Therapy with Low-Dose Weekly Methotrexate (5 mg taken 24 hours after weekly methotrexate to prevent mucositis, hepatotoxicity, and cytopenia!)..

4. Therapeutic Indications & Evidence-Supported Uses

  • Prevention of Neural Tube Defects (spina bifida, anencephaly): 400 mcg/day starting at least 1–3 months before conception through Week 12 of pregnancy (5 mg/day if prior NTD history, diabetic mother, or mother taking Valproate/Carbamazepine!)
  • Folate-Deficiency Megaloblastic Anaemia and chronic haemolytic states (thalassaemia, sickle cell anaemia—5 mg OD lifelong to support rapid erythropoiesis)
  • Mandatory Co-Therapy with Low-Dose Weekly Methotrexate (5 mg taken 24 hours after weekly methotrexate to prevent mucositis, hepatotoxicity, and cytopenia!)

🇮🇳 Jurisdiction & Indication Note: Indications and schedules reflect Indian compendial and regulatory records (CDSCO / Indian Pharmacopoeia & NFI / NLEM 2022). Where international reference labels (US FDA DailyMed / NCBI StatPearls) are cited for pharmacokinetic or mechanistic parameters, international approvals do not automatically imply CDSCO approval in India.

5. Educational Dosage Context, Formulations & Administration

Educational Dosing & Regimen Summary: General Adult Reference: Megaloblastic Anaemia / Haemolysis: 5 mg once daily for 4 months (or lifelong in chronic haemolysis). Methotrexate Rescue: 5 mg once to three times weekly on NON-Methotrexate days (e.g., if Methotrexate is taken on Sunday, take Folvite 5 mg on Monday/Wednesday/Friday). Standard Pregnancy NTD Prophylaxis: 400 mcg once daily. Follow physician prescription.

Administration & Meal Timing: With or without food. | Once daily in the morning (or on designated non-methotrexate days).

6. Pharmacokinetics, Metabolism & Renal/Hepatic Adjustment

Absorption & Disposition:
Follows class pharmacokinetic profile detailed in parent monograph [10.8].
Metabolism & Biotransformation:
Renal: Safe across all stages of CKD; dialysable (5 mg OD is routinely supplemented in haemodialysis patients to replace dialysate losses and lower homocysteine). Hepatic: Safe (essential in alcoholic cirrhosis).
Elimination & Renal Adjustment:
Renal: Safe across all stages of CKD; dialysable (5 mg OD is routinely supplemented in haemodialysis patients to replace dialysate losses and lower homocysteine). Hepatic: Safe (essential in alcoholic cirrhosis).
Hepatic Impairment Considerations:
Renal: Safe across all stages of CKD; dialysable (5 mg OD is routinely supplemented in haemodialysis patients to replace dialysate losses and lower homocysteine). Hepatic: Safe (essential in alcoholic cirrhosis).

7. Contraindications, Precautions & High-Risk Warnings

Contraindications & Red-Flag Precautions:
  • CRITICAL DIAGNOSTIC TRAP IN ELDERLY ANAEMIA: Never administer Folic Acid (>0.4–1 mg/day) alone in undiagnosed Megaloblastic Anaemia without first checking or co-administering Vitamin B12! High-dose Folic Acid (5 mg) bypasses the methyl-folate trap to normalise the blood count (Hb and MCV), masking Vitamin B12 deficiency while allowing irreversible Subacute Combined Degeneration of the Spinal Cord and dementia to progress unchecked!

Key Clinical Precautions: Renal: Safe across all stages of CKD; dialysable (5 mg OD is routinely supplemented in haemodialysis patients to replace dialysate losses and lower homocysteine). Hepatic: Safe (essential in alcoholic cirrhosis).

8. Adverse Effects Profile

Common & Mechanism-Related Adverse Effects:
  • Virtually non-toxic (water-soluble excess is excreted in urine); rare allergic rash or mild GI flatulence at 15 mg/day.
  • Masking of Pernicious Anaemia / Vitamin B12 Neuropathy (leading to irreversible paraplegia and neuropathy if B12 is not co-administered!).
Serious / Dose-Limiting Adverse Effects:

    9. Major Drug–Drug, Drug–Food & Drug–Herb Interactions

    • Phenytoin, Phenobarbitone, and Primidone (Enzyme-Inducing Antiepileptics): Bidirectional Interaction! These anticonvulsants deplete serum folate (causing megaloblastic anaemia); conversely, starting high-dose Folic Acid (5 mg/day) acts as a cofactor that accelerates hepatic CYP hydroxylation of Phenytoin—dropping serum Phenytoin levels by 20–40% and triggering breakthrough seizures! 2
    • Methotrexate (Folitrax), Pyrimethamine, Trimethoprim (Cotrimoxazole), and Sulfasalazine: Folate antagonists/absorption blockers
    • (Note: In Rheumatoid Arthritis, taking Folic Acid 24–48 hours after weekly Methotrexate reduces toxicity without reducing anti-arthritic efficacy!)

    10. Clinical Monitoring, Patient Counselling & Storage

    Clinical & Laboratory Monitoring: Monitor clinical parameters per parent monograph [10.8].

    Pharmacist Patient Counselling Points:

    • Patient Counselling Checklist: LASA Counter Safety Check (Folvite vs. Folitrax): Visually show the patient the bright yellow Folvite 5 mg (Folic Acid Vitamin) tablet and contrast it with Folitrax (Methotrexate)! For RA patients on weekly Methotrexate, clearly mark the Folvite strip: 'Take Folvite on [Monday / Wednesday / Friday]—NEVER take Folvite at the exact same hour as your Sunday Folitrax tablet!'
    • Meal & Clock Timing Instruction: With or without food. (Once daily in the morning (or on designated non-methotrexate days).)
    • Missed Dose Protocol: Take as soon as remembered on the same day (unless it is the patient's weekly Methotrexate day!).
    • Geriatric Dispensing Pearl: In any elderly CGHS patient prescribed Folvite 5 mg for macrocytic anaemia, verify that Serum Vitamin B12 has been tested or that Methylcobalamin (Nurokind) is co-prescribed.

    Storage, Stability & Dispensing Safeguards: Store below 25°C–30°C in original moisture- and light-resistant packaging out of reach of children. Available forms: Oral Uncoated Tablets: 5 mg (5000 mcg — Therapeutic/Haematinic & Methotrexate Rescue); Periconceptional Prophylaxis Tablets: 400 mcg (0.4 mg) / 500 mcg (0.5 mg)

    11. Visual Pharmacology & Mechanism Diagram (svg-v339-01-adme-12-step-journey)

    THE 12-STEP ORAL DRUG JOURNEY THROUGH THE HUMAN BODY (LADME) Note: IV bolus enters Step 6 directly (F = 100%); Sublingual & Transdermal routes bypass Step 4–5 Portal First-Pass Metabolism 1. Oral Administration • Tablet / Capsule swallowed • Gastric emptying to duodenum pH 1.5–3.5 (Stomach) 2. Disintegration & Dissolution • Tablet breaks into granules • API dissolves in GI fluid Noyes-Whitney Dissolution Rate 3. GI Epithelial Absorption • Crosses intestinal villi • Passive / Active / P-gp efflux Small Intestine (Large Surface Area) 4. Portal Circulation • Mesenteric veins → Portal vein • Delivers blood to liver sinusoids Pre-systemic Venous Conduit 5. First-Pass Metabolism • Gut & hepatic CYP450 extraction • High: GTN, Propranolol, Morphine Determines Bioavailability (F = f_a × (1-E_H)) 6. Systemic Circulation • Hepatic vein → IVC → Heart • Unbound vs Albumin-bound drug Only FREE drug is active 7–8. Tissue Distribution (Vd) • Capillary permeation to organs • Blood-Brain & Placental barriers Vd = Dose / C_0 (L or L/kg) 9. Target Site of Action • Receptors (GPCR, Ion channel) • Enzymes & Carrier Transporters Pharmacodynamic Effect (E_max, EC50) 10. Hepatic Biotransformation • Phase I (CYP450 Oxidation/Hydrolysis) • Phase II (Glucuronidation/Sulfation) Converts lipophilic drug → hydrophilic metabolite 11. Renal & Biliary Elimination • Nephron: Filtration + Secretion − Reabsorption • Biliary excretion & Enterohepatic recycling Total Clearance CL_tot = CL_renal + CL_hepatic 12. Excretion from the Body • Urine (Primary polar metabolite route) • Bile/Faeces, Expired Air, Sweat, Milk Elimination Half-Life t1/2 = (0.693 × Vd) / CL
    svg-v339-01-adme-12-step-journey — 8.1 Complete 12-Step Journey of an Orally Administered Drug (ADME): Figure 8.1: The 12-step physiological journey of a typical orally administered solid dosage form through Liberation, Absorption, Distribution, Metabolism, and Excretion (LADME). Note: Parenteral (IV), sublingual, and inhalational routes bypass gastrointestinal absorption and/or hepatic first-pass metabolism.

    12. Authoritative References, Regulatory Sources & Editorial Disclaimer

    Primary Compendial & Guideline Reference: Indian Pharmacopoeia (IP 2022) • NFI • CDSCO

    Official Verification Portals: Indian Pharmacopoeia Commission (IPC) & National Formulary of India (NFI) • Central Drugs Standard Control Organization (CDSCO) • Ministry of Health & Family Welfare — NLEM 2022 • NCBI Bookshelf / StatPearls Pharmacology Reference • DailyMed (US FDA Official Prescribing Reference)

    Last Medically & Pharmaceutically Reviewed: 2026-11-10 • Verification Status: VERIFIED_EDUCATIONAL_CONTENT

    Educational & Clinical Disclaimer: This reference profile is published solely for pharmacy education, academic study, and professional clinical reference. It does not substitute for patient-specific clinical judgement, qualified specialist oncology/medical supervision, or official CDSCO/IP prescribing information. Never self-medicate with prescription, Schedule H/H1/X, NDPS, or oncology medicines.